日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Leveraging Egocentric Social Network Methodology to Understand Risk and Resiliency in Alzheimer’s Disease

利用以自我为中心的社交网络方法论来理解阿尔茨海默病中的风险和韧性

Wagner, S L; Geddes, J W; Cotman, C W; Lau, A L; Gurwitz, D; Isackson, P J; Cunningham, D D; Perry, Brea; Peng, Siyun

Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy

营养状况对接受围手术期FLOT疗法治疗的局部晚期食管胃腺癌的病理反应和无复发生存期的影响

Sugiyama, K; Kumar, S; Chaudry, A; Patel, N; Patel, P; Cunningham, D; Starling, N; Rao, S; Fribbens, C; Eldridge, L; Chau, I

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study

Tislelizumab 与化疗作为欧洲和北美晚期或转移性食管鳞状细胞癌患者二线治疗的比较:一项随机 III 期 RATIONALE-302 研究的亚组分析

Ajani, J; El Hajbi, F; Cunningham, D; Alsina, M; Thuss-Patience, P; Scagliotti, G V; Van den Eynde, M; Kim, S-B; Kato, K; Shen, L; Li, L; Ding, N; Shi, J; Barnes, G; Van Cutsem, E

Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE

多马替诺(4SC-202)联合阿维鲁单抗治疗既往接受过治疗的晚期错配修复功能正常的食管胃癌和结直肠腺癌患者的II期临床试验:EMERGE

Cartwright, E; Slater, S; Saffery, C; Tran, A; Turkes, F; Smith, G; Aresu, M; Kohoutova, D; Terlizzo, M; Zhitkov, O; Rana, I; Johnston, E W; Sanna, I; Smyth, E; Mansoor, W; Fribbens, C; Rao, S; Chau, I; Starling, N; Cunningham, D

Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study

一线化疗后接受度伐利尤单抗维持治疗HER2阴性晚期食管胃腺癌患者的疗效:来自随机PLATFORM研究的结果

Fong, C; Patel, B; Peckitt, C; Bourmpaki, E; Satchwell, L; Cromarty, S; Kidd, S; von Loga, K; Uhlik, M; Begum, R; Rana, T; Waddell, T; Darby, S; Bradshaw, A; Roques, T; Morgan, C; Rees, C; Herbertson, R; Das, P; Thompson, C; Hewish, M; Petty, R; Thistlethwaite, F; Rao, S; Starling, N; Chau, I; Cunningham, D

Quality assessment of online patient information on upper gastrointestinal endoscopy using the modified Ensuring Quality Information for Patients tool

使用改进的“确保患者信息质量”工具对上消化道内镜检查的在线患者信息进行质量评估

Chien, S; Miller, Ghl; Huang, I; Cunningham, D A; Carson, D; Gall, L S; Khan, K S

Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland

爱尔兰共和国结节性硬化症(TSC)患者及其家庭面临的服务碎片化问题十分普遍

Vasseghi, M; Behan, C; Connolly, A; Cunningham, D; Dempsey, E; Flynn, C; Galvin, M; Griffin, G; Moloney, P; Murphy, M; Owen, Y; O'Malley, S; O'Rourke, G; O'Sullivan, O; Doherty, C P

CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial

CXD101 联合纳武利尤单抗治疗转移性微卫星稳定型结直肠癌患者(CAROSELL):一项多中心、开放标签、单臂 II 期试验

Saunders, M P; Graham, J; Cunningham, D; Plummer, R; Church, D; Kerr, R; Cook, S; Zheng, S; La Thangue, N; Kerr, D

Inguinal hernia repair: a systematic analysis of online patient information using the Modified Ensuring Quality Information for Patients tool

腹股沟疝修补术:使用改良版“确保患者信息质量”工具对在线患者信息进行系统分析

Chien, S; Cunningham, D; Khan, K S

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

随机临床试验中入组的弥漫性大B细胞淋巴瘤(DLBCL)患者的24个月无进展生存期(PFS24)及后续结局

Maurer, M J; Habermann, T M; Shi, Q; Schmitz, N; Cunningham, D; Pfreundschuh, M; Seymour, J F; Jaeger, U; Haioun, C; Tilly, H; Ghesquieres, H; Merli, F; Ziepert, M; Herbrecht, R; Flament, J; Fu, T; Flowers, C R; Coiffier, B